Skip to content

US · FMS · MEDICAL - CARE FACILITIES

Fresenius Medical Care AG & Co. KGaA (FMS) intrinsic value and stock valuation

$20.44as of 2026-11-21 · Mkt cap 12.83B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Fresenius Medical Care AG & Co. KGaA DCF and intrinsic value

InvestorsCraft values FMS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FMS’s statements →

Fresenius Medical Care AG & Co. KGaA Graham Number

Graham Number: $30.45d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities Bad Homburg, HE 61352 freseniusmedicalcare.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$19.6B+1.9% 5y CAGRd
20112025
Net income
$978.4M-3.4% 5y CAGRd
20112025
Free cash flow
$1.7B-11.8% 5y CAGRd
20112025
Total equity
$14.3B+3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$19.6B$19.3B$19.5B$19.4B$17.6B
Operating income$1.83B$1.47B$1.37B$1.51B$1.85B
Net income$978.4M$537.9M$499M$673.4M$969.3M
EPSd$1.68M$916.6K$850.3K$574.1K$827.2K
Operating cash flow$2.58B$2.39B$2.63B$2.17B$2.49B
Capital expenditure-$-879.24M-$-699.36M-$-684.6M-$-723.99M-$-854.36M
Free cash flow$1.7B$1.69B$1.94B$1.44B$1.64B
Total assets$31B$33.6B$33.9B$35.8B$34.4B
Total debt$10.8B$11B$12.1B$13.2B$13.3B
Net debt$9.2B$9.82B$10.7B$11.9B$11.8B
Total equity$14.3B$15.8B$14.8B$15.4B$14B
Cash and short-term investments$1.6B$1.34B$1.56B$1.46B$1.64B
Income statement
20252024202320222021
Revenue$19.6B$19.3B$19.5B$19.4B$17.6B
Cost of revenue$14.6B$14.6B$14.5B$14.5B$12.8B
Gross profit$5.03B$4.76B$4.93B$4.89B$4.77B
Research and development expenses$158M$183.5M$232M$228.6M$220.8M
Selling, general and administrative expenses$3.03B$3.14B$3.2B$3.17B$2.77B
Other expenses$11.4M-$-37.04M$127.3M-$-17.06M-$-72.87M
Operating expenses$3.2B$3.29B$3.56B$3.38B$2.92B
Cost and expenses$17.8B$17.9B$18.1B$17.9B$15.8B
Interest income$69.6M$71.6M$88.2M$67.7M$73.2M
Interest expense$384.4M$407M$424.6M$360.1M$353.6M
Depreciation and amortization$1.5B$1.74B$1.75B$1.84B$1.62B
Ebitda$3.4B$3.21B$3.21B$3.42B$3.55B
Operating income$1.83B$1.47B$1.37B$1.51B$1.85B
Total other income/expenses, net-$-314.59M-$-410.45M-$-336.42M-$-292.48M-$-280.43M
Income before tax$1.51B$1.06B$1.03B$1.22B$1.57B
Income tax expense$321M$316.1M$300.6M$325M$352.8M
Net income$978.4M$537.9M$499M$673.4M$969.3M
Weighted average shares outstanding$582.4M$587.9M$587.1M$1.17B$1.17B
Weighted average diluted shares outstanding$582.4M$586.8M$586.8M$1.17B$1.17B
Balance sheet
20252024202320222021
Cash and short-term investments$1.6B$1.34B$1.56B$1.46B$1.64B
Net receivables$3.14B$3.41B$3.64B$3.72B$3.58B
Inventory$2.14B$2.07B$2.18B$2.3B$2.04B
Total current assets$7.9B$7.92B$8.7B$8.2B$7.97B
Property, plant and equipment, net$3.01B$7.26B$7.45B$8.34B$8.55B
Goodwill and intangible assets$14.8B$16.5B$16B$17.3B$15.8B
Long-term investments$0.00$1.12B$1.08B$1.2B$786.9M
Total non-current assets$23.1B$25.6B$25.2B$27.6B$26.4B
Total assets$31B$33.6B$33.9B$35.8B$34.4B
Accounts payable$738M$984.3M$885.2M$951.6M$857.5M
Short-term debt$2.2B$1.22B$1.56B$2.02B$2.59B
Deferred revenue$0.00$82.2M$85.8M$105.7M$518M
Total current liabilities$6.25B$5.66B$6.11B$6.47B$7.26B
Long-term debt$8.6B$9.76B$10.5B$11.2B$10.7B
Deferred revenue, non-current$0.00$34M$13.9M$9.47M$0.00
Total non-current liabilities$10.5B$12.1B$13B$13.8B$13.1B
Capital lease obligations$3.49B$4.14B$4.15B$4.68B$4.75B
Total liabilities$16.7B$17.8B$19.1B$20.3B$20.4B
Common stock$14.3B$293.4M$293.4M$293.4M$293M
Retained earnings$0.00$11.3B$10.9B$10.7B$10.8B
Accumulated other comprehensive income (loss)$0.00-$-328.55M-$-975.17M-$-388.47M-$-1.31B
Total equity$14.3B$15.8B$14.8B$15.4B$14B
Total investments$0.00$1.29B$1.23B$1.39B$946.1M
Total debt$10.8B$11B$12.1B$13.2B$13.3B
Net debt$9.2B$9.82B$10.7B$11.9B$11.8B
Cash flow statement
20252024202320222021
Net income$939.8M$740.9M$732.5M$894.3M$1.22B
Depreciation and amortization$1.41B$1.74B$1.75B$1.84B$1.62B
Stock-based compensation$0.00$0.00$32.5M$0.00$0.00
Change in working capital$132.8M$444.3M$561.3M-$-128.07M-$-97.77M
Accounts receivable-$-66.34M-$-73.48M-$-151.84M-$-46.68M-$-163.2M
Inventory-$-238.84M$107.9M-$-13.14M-$-204.31M-$-48.53M
Accounts payable-$-14.18M$155.6M$108.5M-$-356.79M-$-363.95M
Net cash provided by operating activities$2.58B$2.39B$2.63B$2.17B$2.49B
Investments in property, plant and equipment-$-883.73M-$-699.36M-$-684.6M-$-723.99M-$-854.36M
Acquisitions, net$223.3M$606.7M$137M$1.03M-$-381.73M
Net cash used for investing activities-$-666.18M-$-84.94M-$-544.23M-$-734.73M-$-1.2B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-562.19M$0.00$0.00$0.00$0.00
Dividends paid-$-405.84M-$-349.16M-$-328.62M-$-395.56M-$-392.45M
Net cash used for financing activities-$-1.38B-$-2.57B-$-1.86B-$-1.62B-$-1.02B
Net change in cash$558.3M-$-241.9M$153.4M-$-207.87M$400.1M
Cash at end of period$1.6B$1.19B$1.43B$1.27B$1.48B
Operating cash flow$2.58B$2.39B$2.63B$2.17B$2.49B
Capital expenditure-$-879.24M-$-699.36M-$-684.6M-$-723.99M-$-854.36M
Free cash flow$1.7B$1.69B$1.94B$1.44B$1.64B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Fresenius Medical Care AG & Co. KGaA

        Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

        CEO
        Helen Giza
        Employees
        108.17K
        Beta
        0.76

        Explore

        Frequently asked questions

        What is the intrinsic value of Fresenius Medical Care AG & Co. KGaA (FMS)?

        Fresenius Medical Care AG & Co. KGaA (FMS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is FMS undervalued?

        FMS trades at a price of $20.44 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.